6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
TRADJENTA O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
included O
nasopharyngitis O
( O
6.1 O
) O
* O
Hypoglycemia O
was O
more O
commonly O
reported O
in O
patients O
treated O
with O
the O
combination O
of O
TRADJENTA O
and O
sulfonylurea O
compared O
with O
those O
treated O
with O
the O
combination O
of O
placebo O
and O
sulfonylurea O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Boehringer O
Ingelheim O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-542-6257 O
or O
1-800-459-9906 O
TTY O
, O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
evaluation O
of O
TRADJENTA O
5 O
mg O
once O
daily O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
is O
based O
on O
14 O
placebo-controlled O
trials O
, O
1 O
active-controlled O
study O
, O
and O
one O
study O
in O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

In O
the O
14 O
placebo-controlled O
studies O
, O
a O
total O
of O
3625 O
patients O
were O
randomized O
and O
treated O
with O
TRADJENTA O
5 O
mg O
daily O
and O
2176 O
with O
placebo O
. O

The O
mean O
exposure O
in O
patients O
treated O
with O
TRADJENTA O
across O
studies O
was O
29.6 O
weeks O
. O

The O
maximum O
follow-up O
was O
78 O
weeks O
. O

TRADJENTA O
5 O
mg O
once O
daily O
was O
studied O
as O
monotherapy O
in O
three O
placebo-controlled O
trials O
of O
18 O
and O
24 O
weeks O
' O
duration O
and O
in O
five O
additional O
placebo-controlled O
studies O
lasting O
< O
=18 O
weeks O
. O

The O
use O
of O
TRADJENTA O
in O
combination O
with O
other O
antihyperglycemic O
agents O
was O
studied O
in O
six O
placebo-controlled O
trials O
: O
two O
with O
metformin O
( O
12 O
and O
24 O
weeks O
' O
treatment O
duration O
) O
; O
one O
with O
a O
sulfonylurea O
( O
18 O
weeks O
' O
treatment O
duration O
) O
; O
one O
with O
metformin O
and O
sulfonylurea O
( O
24 O
weeks O
' O
treatment O
duration O
) O
; O
one O
with O
pioglitazone O
( O
24 O
weeks O
' O
treatment O
duration O
) O
; O
and O
one O
with O
insulin O
( O
primary O
endpoint O
at O
24 O
weeks O
) O
. O

In O
a O
pooled O
dataset O
of O
14 O
placebo-controlled O
clinical O
trials O
, O
adverse O
reactions O
that O
occurred O
in O
> O
=2 O
% O
of O
patients O
receiving O
TRADJENTA O
( O
n O
= O
3625 O
) O
and O
more O
commonly O
than O
in O
patients O
given O
placebo O
( O
n O
= O
2176 O
) O
, O
are O
shown O
in O
Table O
1 O
. O

The O
overall O
incidence O
of O
adverse O
events O
with O
TRADJENTA O
were O
similar O
to O
placebo O
. O

Table O
1 O
Adverse O
Reactions O
Reported O
in O
> O
=2 O
% O
of O
Patients O
Treated O
with O
TRADJENTA O
and O
Greater O
than O
Placebo O
in O
Placebo-Controlled O
Clinical O
Studies O
of O
TRADJENTA O
Monotherapy O
or O
Combination O
Therapy O
Number O
( O
% O
) O
of O
Patients O
TRADJENTA O
5 O
mgn O
= O
3625 O
Placebon O
= O
2176 O
Nasopharyngitis B-OSE_Labeled_AE
254 O
( O
7.0 O
) O
132 O
( O
6.1 O
) O
Diarrhea B-OSE_Labeled_AE
119 O
( O
3.3 O
) O
65 O
( O
3.0 O
) O
Cough B-OSE_Labeled_AE
76 O
( O
2.1 O
) O
30 O
( O
1.4 O
) O
Rates O
for O
other O
adverse O
reactions O
for O
TRADJENTA O
5 O
mg O
vs O
placebo O
when O
TRADJENTA O
was O
used O
in O
combination O
with O
specific O
anti-diabetic O
agents O
were O
: O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
3.1 O
% O
vs O
0 O
% O
) O
and O
hypertriglyceridemia B-OSE_Labeled_AE
( O
2.4 O
% O
vs O
0 O
% O
) O
when O
TRADJENTA O
was O
used O
as O
add-on O
to O
sulfonylurea O
; O
hyperlipidemia B-OSE_Labeled_AE
( O
2.7 O
% O
vs O
0.8 O
% O
) O
and O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
2.3 O
% O
vs O
0.8 O
% O
) O
when O
TRADJENTA O
was O
used O
as O
add-on O
to O
pioglitazone O
; O
and O
constipation B-OSE_Labeled_AE
( O
2.1 O
% O
vs O
1 O
% O
) O
when O
TRADJENTA O
was O
used O
as O
add-on O
to O
basal O
insulin O
therapy O
. O

Following O
104 O
weeks O
' O
treatment O
in O
a O
controlled O
study O
comparing O
TRADJENTA O
with O
glimepiride O
in O
which O
all O
patients O
were O
also O
receiving O
metformin O
, O
adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
TRADJENTA O
( O
n O
= O
776 O
) O
and O
more O
frequently O
than O
in O
patients O
treated O
with O
a O
sulfonylurea O
( O
n O
= O
775 O
) O
were O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
9.1 O
% O
vs O
8.4 O
% O
) O
, O
arthralgia B-OSE_Labeled_AE
( O
8.1 O
% O
vs O
6.1 O
% O
) O
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
8.0 O
% O
vs O
7.6 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
6.4 O
% O
vs O
5.2 O
% O
) O
, O
cough B-OSE_Labeled_AE
( O
6.1 O
% O
vs O
4.9 O
% O
) O
, O
and O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
5.3 O
% O
vs O
3.9 O
% O
) O
. O

Other O
adverse O
reactions O
reported O
in O
clinical O
studies O
with O
treatment O
of O
TRADJENTA O
were O
hypersensitivity B-OSE_Labeled_AE
( O
e.g. O
, O
urticaria B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
localized B-OSE_Labeled_AE
skin O
exfoliation I-OSE_Labeled_AE
, O
or O
bronchial B-OSE_Labeled_AE
hyperreactivity I-OSE_Labeled_AE
) O
, O
and O
myalgia B-OSE_Labeled_AE
. O

In O
the O
clinical O
trial O
program O
, O
pancreatitis B-OSE_Labeled_AE
was O
reported O
in O
15.2 O
cases O
per O
10,000 O
patient O
year O
exposure O
while O
being O
treated O
with O
TRADJENTA O
compared O
with O
3.7 O
cases O
per O
10,000 O
patient O
year O
exposure O
while O
being O
treated O
with O
comparator O
( O
placebo O
and O
active O
comparator O
, O
sulfonylurea O
) O
. O

Three O
additional O
cases O
of O
pancreatitis B-OSE_Labeled_AE
were O
reported O
following O
the O
last O
administered O
dose O
of O
linagliptin O
. O

Hypoglycemia O
In O
the O
placebo-controlled O
studies O
, O
199 O
( O
6.6 O
% O
) O
of O
the O
total O
2994 O
patients O
treated O
with O
TRADJENTA O
5 O
mg O
reported O
hypoglycemia B-OSE_Labeled_AE
compared O
to O
56 O
patients O
( O
3.6 O
% O
) O
of O
1546 O
placebo-treated O
patients O
. O

The O
incidence O
of O
hypoglycemia B-NonOSE_AE
was O
similar O
to O
placebo O
when O
TRADJENTA O
was O
administered O
as O
monotherapy O
or O
in O
combination O
with O
metformin O
, O
or O
with O
pioglitazone O
. O

When O
TRADJENTA O
was O
administered O
in O
combination O
with O
metformin O
and O
a O
sulfonylurea O
, O
181 O
of O
792 O
( O
22.9 O
% O
) O
patients O
reported O
hypoglycemia B-OSE_Labeled_AE
compared O
with O
39 O
of O
263 O
( O
14.8 O
% O
) O
patients O
administered O
placebo O
in O
combination O
with O
metformin O
and O
a O
sulfonylurea O
. O

Adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
hypoglycemia B-NonOSE_AE
. O

A O
concurrent O
glucose O
measurement O
was O
not O
required O
or O
was O
normal O
in O
some O
patients O
. O

Therefore O
, O
it O
is O
not O
possible O
to O
conclusively O
determine O
that O
all O
these O
reports O
reflect O
true O
hypoglycemia B-NonOSE_AE
. O

In O
the O
study O
of O
patients O
receiving O
TRADJENTA O
as O
add-on O
therapy O
to O
a O
stable O
dose O
of O
insulin O
for O
up O
to O
52 O
weeks O
( O
n=1261 O
) O
, O
no O
significant O
difference O
in O
the O
incidence O
of O
investigator O
reported O
hypoglycemia B-NonOSE_AE
, O
defined O
as O
all O
symptomatic O
or O
asymptomatic O
episodes O
with O
a O
self-measured O
blood B-NonOSE_AE
glucose I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
7 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
, O
was O
noted O
between O
the O
TRADJENTA- O
( O
31.4 O
% O
) O
and O
placebo- O
( O
32.9 O
% O
) O
treated O
groups O
. O

During O
the O
same O
time O
period O
, O
severe O
hypoglycemic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
defined O
as O
requiring O
the O
assistance O
of O
another O
person O
to O
actively O
administer O
carbohydrate O
, O
glucagon O
or O
other O
resuscitative O
actions O
, O
were O
reported O
in O
11 O
( O
1.7 O
% O
) O
of O
TRADJENTA O
treated O
patients O
and O
7 O
( O
1.1 O
% O
) O
of O
placebo O
treated O
patients O
. O

Events O
that O
were O
considered O
life-threatening O
or O
required O
hospitalization O
were O
reported O
in O
3 O
( O
0.5 O
% O
) O
patients O
on O
TRADJENTA O
and O
1 O
( O
0.2 O
% O
) O
on O
placebo O
. O

Use O
in O
Renal B-NonOSE_AE
Impairment I-NonOSE_AE
TRADJENTA O
was O
compared O
to O
placebo O
as O
add-on O
to O
pre-existing O
antidiabetic O
therapy O
over O
52 O
weeks O
in O
133 O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
estimated O
GFR B-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
) O
. O

For O
the O
initial O
12 O
weeks O
of O
the O
study O
, O
background O
antidiabetic O
therapy O
was O
kept O
stable O
and O
included O
insulin O
, O
sulfonylurea O
, O
glinides O
, O
and O
pioglitazone O
. O

For O
the O
remainder O
of O
the O
trial O
, O
dose O
adjustments O
in O
antidiabetic O
background O
therapy O
were O
allowed O
. O

In O
general O
, O
the O
incidence O
of O
adverse O
events O
including O
severe O
hypoglycemia B-OSE_Labeled_AE
was O
similar O
to O
those O
reported O
in O
other O
TRADJENTA O
trials O
. O

The O
observed O
incidence O
of O
hypoglycemia B-OSE_Labeled_AE
was O
higher O
( O
TRADJENTA O
, O
63 O
% O
compared O
to O
placebo O
, O
49 O
% O
) O
due O
to O
an O
increase O
in O
asymptomatic O
hypoglycemic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
especially O
during O
the O
first O
12 O
weeks O
when O
background O
glycemic O
therapies O
were O
kept O
stable O
. O

Ten O
TRADJENTA-treated O
patients O
( O
15 O
% O
) O
and O
11 O
placebo-treated O
patients O
( O
17 O
% O
) O
reported O
at O
least O
one O
episode O
of O
confirmed O
symptomatic O
hypoglycemia B-NonOSE_AE
( O
accompanying O
finger O
stick O
glucose O
< O
=54 O
mg/dL O
) O
. O

During O
the O
same O
time O
period O
, O
severe O
hypoglycemic B-NonOSE_AE
events I-NonOSE_AE
, O
defined O
as O
an O
event O
requiring O
the O
assistance O
of O
another O
person O
to O
actively O
administer O
carbohydrate O
, O
glucagon O
or O
other O
resuscitative O
actions O
, O
were O
reported O
in O
3 O
( O
4.4 O
% O
) O
TRADJENTA-treated O
patients O
and O
3 O
( O
4.6 O
% O
) O
placebo-treated O
patients O
. O

Events O
that O
were O
considered O
life-threatening O
or O
required O
hospitalization O
were O
reported O
in O
2 O
( O
2.9 O
% O
) O
patients O
on O
TRADJENTA O
and O
1 O
( O
1.5 O
% O
) O
patient O
on O
placebo O
. O

Renal O
function O
as O
measured O
by O
mean O
eGFR O
and O
creatinine O
clearance O
did O
not O
change O
over O
52 O
weeks O
' O
treatment O
compared O
to O
placebo O
. O

Laboratory O
Tests O
Changes O
in O
laboratory O
findings O
were O
similar O
in O
patients O
treated O
with O
TRADJENTA O
5 O
mg O
compared O
to O
patients O
treated O
with O
placebo O
. O

Changes B-NonOSE_AE
in I-NonOSE_AE
laboratory I-NonOSE_AE
values I-NonOSE_AE
that O
occurred O
more O
frequently O
in O
the O
TRADJENTA O
group O
and O
> O
1 O
% O
more O
than O
in O
the O
placebo O
group O
were O
increases B-OSE_Labeled_AE
in O
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
( O
1.3 O
% O
in O
the O
placebo O
group O
, O
2.7 O
% O
in O
the O
TRADJENTA O
group O
) O
. O

No O
clinically O
meaningful O
changes O
in O
vital O
signs O
were O
observed O
in O
patients O
treated O
with O
TRADJENTA O
. O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
TRADJENTA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
pancreatitis B-OSE_Labeled_AE
[ O
see O
Indications O
and O
Usage O
( O
1.2 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Rash B-OSE_Labeled_AE
* O
Mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE

